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Abstract
Introduction. Docosahexaenoic acid (DHA) has been shown to have beneficial effects on Parkinson’s disease 
(PD). The aim of this study was to investigate if the DHA acts on neurons of substantia nigra (SN) by phospho-
rylation of neuronal nitric oxide synthase (nNOS) in an experimental mouse model of PD. 
Material and methods. An experimental model of PD was created by intraperitoneal injections (4 × 20 mg/kg) 
of the neurotoxin 1-methyl-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Three-month-old male C57BL/6 mice 
were randomly divided into four groups as follows: control (C), DHA-treated (DHA), MPTP-injected (MPTP) 
and DHA-treated and MPTP-injected (DHA + MPTP). DHA (36 mg/kg/day) was administered daily by gavage 
for four weeks. Motor activity of the mice was evaluated with pole, locomotor activity and rotarod tests. Caspase-3 
activity, nitrate/nitrite and 4-hydroxynonenal (4-HNE) levels were determined by spectrophotometric assays. 
Immunohistochemistry was used to localize and assess the expressions of tyrosine hydroxylase (TH), nNOS and 
phospho-nNOS (p-nNOS) in SN. 
Results. An increased return and total down time in the MPTP group was observed in the pole test, while DHA 
treatment decreased both parameters. The ambulatory activity, total distance and total locomotor activities were 
decreased in the MPTP group, whereas they were increased by DHA treatment. MPTP-treated animals exhibited 
shorter time on the rod test which was significantly increased by DHA treatment. DHA administration signifi-
cantly decreased 4-HNE and nitrate/nitrite levels of SN supernatants and protected the TH (+) dopaminergic 
neurons of SN in the DHA + MPTP group compared to the MPTP group. DHA treatment significantly decreased 
nNOS and increased p-nNOS immunoreactivities in the DHA + MPTP group compared to the MPTP group. 
Conclusions. These results indicate that DHA treatment protects dopaminergic neurons in SN via increasing 
nNOS serine 852 phosphorylation in the experimental mice model of PD. (Folia Histochemica et Cytobiologica 
2018, Vol. 56, No. 1, 27–37)
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Introduction
Parkinson’s disease (PD) was first described in 1817 
by Dr. James Parkinson; it is the most common neu-
rodegenerative disease after Alzheimer’s disease [1, 
2]. Parkinson’s disease results mainly from the death 
of dopaminergic neurons in the substantia nigra (SN). 
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The definitive cause of PD is not entirely known but 
hypotheses such as some traumas [3], ageing [4], 
a-synuclein accumulation [5], genetic inclination and 
misfolded proteins [6], mitochondrial abnormalities 
[7], inflammation [8] and microglial activity [9] are 
being proposed. 
One of the most important hypotheses of PD is 
the increased level of free radicals in SN. The for-
mation of free radicals leads to the peroxidation of 
lipids [10]. Nitric oxide (NO) is a neurotransmitter in 
the nervous system that is synthesized by the enzyme 
nitric oxide synthase (NOS). It is known to produce 
nitrogen derivatives like nitrite and nitrate in the 
presence of oxygen and acts like a radical. It has also 
been shown that NO reacts with oxygen radicals and 
superoxides to form peroxynitrite (ONOO–) [11]. It 
has been shown that the phosphorylation of different 
nNOS residues has different cellular effects. nNOS 
can be phosphorylated by various enzymes [12]. Being 
phosphorylated at serine 1412 increases nNOS activity 
[13], while nNOS is inhibited by phosphorylation at 
Ser847 [14].
Omega-3 polyunsaturated fatty acids (PUFAs) 
exhibit neuroprotective properties and represent 
a potential treatment for various kinds of neuro-
degenerative disorders [15]. It has been identified 
that the primary PUFA of the brain phospholipids is 
docosahexaenoic acid (DHA) which can affect nNOS 
and inducible NOS (iNOS) activities [16]. 
It is known that iNOS expression and nNOS 
activity increases in substantia nigra pars compacta 
(SNpc) after the administration of the neurotoxin 
1-methyl-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) 
which is being used to create an experimental PD 
model [17]. In a previous study [18], it has been shown 
that nNOS plays a role in the death of dopaminergic 
neurons in SN. It was shown in the experimental PD 
models that DHA prevents the death of dopaminergic 
neurons containing tyrosine hydroxylase (TH) [19]. It 
is known that DHA affects neuronal cell membrane 
channels and intercellular signaling pathways acti-
vated by molecules such as adhesion proteins [20]. It 
was established that DHA has neuroprotective effects 
in experimental PD models [21]. However, it is not 
known whether the phosphorylation of nNOS at the 
serine 852 region that corresponds to Ser847 in the 
mouse and nNOS inhibition play a role in the pro-
tective effects of DHA in the experimental model of 
PD. This study was aimed to identify the role of DHA 
on nigral nNOS phosphorylation in an experimental 
mice model of PD and the results were supported by 
biochemical and motor parameters. 
Materials and methods
Animals. Animal maintenance and treatment were carried 
out in accordance with the Institutional Animal Care and Use 
Committee at Akdeniz University Medical School, Antalya, 
Turkey. Male C57BL/6 mice (three months old, 25–30 g) 
were obtained from Akdeniz University Animal Care 
Unit. Animals were housed at an ambient temperature of 
23 ± 2°C, in a 12 h light/dark cycle and were fed standard mice 
chow and tap water ad libitum up to day of the experiments.
Drug administration. One hundred male mice were random-
ly divided into 4 groups: control (C), DHA-treated (DHA), 
MPTP-injected (MPTP), DHA-treated and MPTP-injected 
(DHA + MPTP). DHA (36 mg/kg/day) was administered 
daily by gavage for four weeks to DHA and DHA + MPTP 
groups [22]. The experimental PD model was utilized by 
consecutive intraperitoneal (i.p.) injections of MPTP neu-
rotoxin (4 × 20 mg/kg) at 2-h intervals on the 23rd day of 
the experimental schedule [17].
Assessment of behavioral activity
Measurement of motor activity. Motor activity of the mice 
was evaluated by “pole test” (as a marker for the intensity 
of bradykinesia, a typical symptom of PD) as well as the 
locomotor activity and rotarod tests [23–27]. All of the tests 
were performed on the 7th day after the injection of MPTP.
Pole test. The pole test is used to assess basal ganglia-relat-
ed movement disorders in mice. To determine the degree 
of bradykinesia, the pole test was performed according to 
Ogawa et al. with minor modifications [23, 24]. Animals 
were placed head-up on top of a rough-surfaced iron pole 
(50 cm in length and 0.8 cm in diameter). The base of the 
pole is placed in a cage filled with bedding material. Sticking 
plaster was wrapped around the iron pole to increase trac-
tion. When placed on the pole, animals orient themselves 
downward and descend the length of the pole back into the 
cage. Trials were eliminated if the mouse jumped or slid 
down the pole rather than climbed down. After two days 
of training, animals were subjected to test trials. The time 
it took for the animal to turn (T-Turn) its head downwards 
(movement initiation) and t-turn + climb down the entire 
length of the pole (total turn time) was recorded. Averages 
of the best three measurements were taken as results.
Locomotor activity test. Locomotor activity was measured 
with an open-field activity monitoring system (MAY 9908 
model Activity Monitoring System: Commat Ltd, Ankara, 
Turkey) [25]. Each of the eight locomotor activity chambers 
is a clear Plexiglas box (42 cm L × 42 cm W × 30 cm H) 
equipped with infrared photocells. These cages contain 
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fifteen photocell emitter and detector pairs that are mount-
ed on opposite walls (2 cm above the chamber floor), and 
another 15 photocell pairs were located 8 cm above the 
floor. Breaks of the photocell beams were recorded by 
a computer system and the mouse’s position in the chamber 
was calculated by the software at 0.1 s sensitivity. If the 
calculated locations were completely changed, this was 
expressed as ambulatory activity. Total distance moved and 
the total locomotor activity was recorded, too. For testing 
all parameters one mouse was placed in the center of the 
open field cage and its activity was recorded for 5 min. Before 
placing another animal, the open field was cleaned with 10% 
ethanol to attenuate odors.
Rotarod test. A rotarod test was used to determine the motor 
coordination and balance of the mice [26, 27]. For three con-
secutive days, mice were trained to the rotarod apparatus. 
On testing day, mice were habituated to the testing room 
for 30 min. Then they were placed on a rotating rod (model 
7650 Rota-rod, Ugo Basile, Collegeville, PA, USA) that 
has rotating speed of 5, 10, 20, 30 or 40 rpm. The maximum 
duration of each trial was 5 min. The time that the mice fell 
off the rod was recorded. There were 5 min breaks between 
each recording speeds. Latency to fall was measured.
Tissue collection. After motor performance tests, at the 
end of the treatment period, mice were anesthetized with 
urethane (1 g/kg, i.p.) diluted in saline. Mice were perfused 
transcardially with heparinized saline and their brains were 
removed immediately, SN areas dissected and stored at 
−80°C for later biochemical analysis. For immunohisto-
chemical (IHC) analysis, mice were perfused transcardially 
with heparinized saline and then with 10% formalin. Total 
brain tissues were removed and fixed in 10% formalin for 
6 h and washed with tap water for approximately 2 h.
Immunohistochemistry. For the detection of TH, nNOS 
and phospho-nNOS (p-nNOS) immunoreactivities, paraffin 
sections were deparaffinized in xylene and rehydrated in a 
graded series of ethanol. Sections were immersed in 3% 
hydrogen peroxide in methanol for 15 min to block endog-
enous peroxidase activity. Slides were then incubated with a 
universal blocking reagent (TA-125-UB, LabVision Ultra V 
Block, Fremont, CA, USA) for 7 min at room temperature 
(RT). Afterwards, excess serum was drained and sections 
were incubated with primary antibodies; rabbit polyclonal 
anti-TH (1/800; #ab-112, Abcam, Cambridge, UK), rab-
bit polyclonal anti-nNOS (1/200; #ab-106417, Abcam) 
and rabbit polyclonal anti-nNOS (phospho S852, 1/200; 
#ab-58533, Abcam) in a humidified chamber overnight 
at 4°C. For negative controls, the primary antibodies were 
replaced by phosphate-buffered saline (PBS). After several 
washes in PBS, sections were incubated with biotinylated 
goat anti-rabbit IgG antibody (1/400; #BA-1000, Vector, 
Burlingame, CA, USA) for 30 min followed by incubation 
with LSAB streptavidin-peroxidase complex (Vector ABC 
kit, VECTOR, #PK400) for 45 min and were rinsed with 
PBS. Antibody complexes were visualized by incubation 
with diaminobenzidine (DAB) chromogen (TA-125-HD, 
DAB chromogen Substrate System, THERMO). Sections 
were counterstained with Mayer’s hematoxylin (Dako, 
Glostrup, Denmark), dehydrated, mounted and examined 
by an Axioplan microscope (Zeiss, Oberkochen, Germany). 
The images were taken using a 5MP Canon A95 camera 
integrated to the microscope (Canon, Tokyo, Japan). TH 
immunoreactivity was evaluated using image-J analysis 
(NIH, Bethesda, MD, USA). Three randomly selected 
slides, each of ten different fields of SN were evaluated at 
40× objective magnification. The distinct labeled cells with 
observed immunostaining were counted in every μm2.
Biochemical measurements
Nitrate/nitrite assay. To determine total NO production in 
SN tissues, the levels of nitrate and nitrite that represent oxi-
dized forms of NO, were determined in the SN supernatants 
by the use of nitrate/nitrite commercial colorimetric assay kit 
(CAYMAN-780001, Cayman Chemical Co, Ann Arbor, MI, 
USA). Whole SN tissues were weighed and homogenized 
in 20 ml of PBS per gram tissue on ice and centrifuged at 
17,500 rpm for 20 min. Supernatants were collected and 
stored at –80°C. In this method, the nitrate in the SN sam-
ples was converted into nitrite by nitrate reductase, and 
the total nitrite levels were determined as the total nitrate/
nitrite (NOx). Absorbance was read at 550 nm and nitrate/
nitrite values were expressed as nanomole per mg protein. 
4-hydroxynonenal (4-HNE) assay. (4-HNE)-His Adduct Elisa 
kit (OxiSelect HNE-STA-334, San Diego, CA, USA) was 
used to measure lipid peroxidation in SN tissue samples. 
The utilized protocol is an enzyme immunoassay developed 
for detection and quantitation of HNE-His protein ad-
ducts. Whole SN tissues were weighed and homogenized in 
20 ml of PBS per gr tissue on ice and assayed for quantitation 
of HNE-His protein adduct according to manufacturer’s 
instructions. The absorbance of samples were measured at 
450 nm and the quantity of HNE adduct was expressed as ng 
per μg of tissue protein.
Caspase-3 activity assay. Caspase-3 activities in SN tissue 
samples were measured by quantifying the cleavage of acetyl-
Asp-Glu-Val-Asp-p-nitroaniline (Ac-DEVD-pNa) with 
a colorimetric caspase-3 activity assay kit (Millipore-APT165, 
Darmstadt, Germany). Whole SN tissues were homogenized 
in 200 μL lysis buffer supplied with the kit and assayed ac-
cording to the manufacturer’s instruction. The absorbance 
was then measured at 405 nm in a microplate reader. The 
activity of the enzyme was calculated as units/mg protein 
and then expressed as fold increase.
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Protein measurement. Protein concentrations were measured 
spectrophotometrically (Shimadzu RF-5500, Kyoto, Japan) 
at 595 nm by a modified Bradford assay [28] using Coomas-
sie Plus reagent with bovine serum albumin as a standard 
(Pierce Chemical Company, Rockford, IL, USA).
Statistical analysis. The statistical analyses were conduct 
by using the SPSS v.23.0 (IBM Corp., Armonk, NY, USA). 
Data are expressed as mean ± SEM. Differences were ana-
lyzed via a one way analysis of variance (ANOVA) followed 
by Tukey’s Post Hoc Test for normally distributed variables 
and Kruskal-Wallis followed up Mann-Whitney U test for 
non-normally distributed variables. P values less than 0.05 




Changes in bradykinesia (slow-down of movements) 
are presented in Figure 1. Time required to turn 
(T-Turn) (A) and total turn time (B) were determined 
for all groups. MPTP-injected mice showed elongat-
ed T-Turn and total turn time as compared with the 
control group. DHA treatment improved T-turn and 
total turn times in DHA + MPTP group compared to 
the MPTP group but the values were still above the 
control group levels.
Locomotor activity
MPTP-injected mice exhibited reduced ambulatory, 
total distance and total locomotor activity compared 
to the control group. These activities increased in 
the DHA + MPTP group compared to the MPTP 
group but did not reach the values of the control 
group (Fig. 2). 
Rotarod 
Rotarod performances were measured for five consec-
utive trials in all groups. It was seen that the time mice 
stayed on the rod rotating at 40 rpm decreased in the 
MPTP group when compared to the control group. 
The treatment with DHA significantly increased the 
time on the rod at 40 rpm in the DHA + MPTP group 
compared to the MPTP group. However, it did not 
reach level of the control group (Fig. 3). 
The immunoreactivity of the studied proteins  
in the substantia nigra 
Tyrosine hydroxylase immunoreactivity
Representative microphotographs of dopaminergic 
neurons that expressed TH immunoreactivity and 
the number of TH-immunostained cells are shown in 
Figure 4. The immunoreactivity for TH was observed 
in neuron bodies. The number of TH-immunoreactive 
(-ir) cells in the MPTP group was significantly lower 
(75%) compared to the control group. Dopaminergic 
neuron number significantly increased two-fold in the 
DHA + MPTP group compared to the MPTP group 
but it did not reach the level of the control group.
Neuronal nitric oxide synthase immunoreactivity 
Representative microphotographs of nNOS immuno-
reactivity of dopaminergic neurons in SN are shown in 
Figure 5. nNOS immunoreactivity was weakly positive 
in neuron cytoplasm (arrowheads) in the control and 
Figure 1. The effect of DHA on bradykinesia in an experimental model of Parkinson’s disease measured by the pole test. 
Mice were treated with docosahexaenoic acid (DHA groups) for 4 weeks and a part of them was injected i.p. with neurotoxin 
MPTP (DHA + MPTP group) at the 23rd day as described in Methods. Some control mice were also treated with MPTP on 
the 23rd day (MPTP group). All animals were sampled after 4 weeks from the beginning of the experiment. A. The time it 
took for the animal to turn (T-Turn) its head downwards. B. T-Turn and climb down the entire length of the pole (total turn 
time) were shown in the graphs. Data are presented as means ± SEM, n = 20 in each group. *p < 0.05 vs. control group, 
#p < 0.05 vs. MPTP group. 
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DHA groups. nNOS showed strong immunoreactivity 
in the MPTP group (arrows). The reactions were 
clearly increased in the MPTP group compared to 
the control group. nNOS immunoreactivity was de-
creased in the DHA + MPTP group compared to the 
MPTP group (arrows) but it was still higher than in 
the control group.
Phosphorylated nNOS immunoreactivity 
Coronal brain sections of SN were immunostained 
with p-nNOS antibody which is a phosphorylation 
marker of nNOS serine 852 region that corresponds 
to Ser847 in the mouse. In these sections, there was 
little immunoreactivity (arrowheads) in the control 
and DHA groups. p-nNOS expression was observed 
in the MPTP group but it was more prominent in the 
Figure 2. The effects of DHA on locomotor activities of 
mice in an experimental model of Parkinson’s disease. The 
experiment was planned and groups of animals designed as 
described in the legend to Figure 1. A. Ambulatory Activity. B. 
Total Distance. C. Total Locomotor Activity (Total LMA) of 
experimental groups. Data are means ± SEM, n = 14 in each 
group. *p < 0.05 vs. control group, #p < 0.05 vs. MPTP group. 
Figure 3. The effect of DHA on rotarod performances of mice in 
an experimental model of Parkinson’s disease. The experiment 
was planned and groups of animals designed as described in 
the legend to Figure 1. Data are means  ±  SEM, n = 10 in each 
group. *p < 0.05 vs. control group. #p < 0.05 vs. MPTP group.
Figure 4. Tyrosine hydroxylase (TH)-immunoreactivity in 
dopaminergic neurons of substantia nigra in brains of mice in 
an experimental model of Parkinson disease. The experiment 
was planned and groups of animals designed as described in the 
legend to Figure 1. A. The number of TH (+) dopaminergic 
neurons was clearly decreased in the MPTP group compared 
to the control group. An increase in dopaminergic neuron 
numbers were seen in the DHA + MPTP group compared to 
the MPTP group. Magnifications are presented as 40×. Scale 
bars — 50 μm. B. The percentage of the number of TH (+) 
neurons in the experimental groups as compared to control 
mice. Data are means ± SEM, n = 5 in each group. *p < 0.05 
vs. control group. #p < 0.05 vs. MPTP group.
Control
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DHA + MPTP group compared to the MPTP group 
(Fig. 6, arrows).
The biochemical parameters in the substantia nigra
Nitrate/nitrite levels 
The levels of nitrate and nitrite, the products of NO 
degradation, were higher in the MPTP group than 
in the control group. The treatment with DHA of 
MPTP-treated mice decreased nitrate/nitrite levels 
compared to the MPTP group without reaching the 
control group levels (Fig. 7). 
4-HNE levels
4-HNE is an indicator of lipid peroxidation. The level 
of nigral 4-HNE increased in the MPTP group com-
pared to the control group. DHA treatment decreased 
the level of nigral 4-HNE in the DHA + MPTP group 
compared to the MPTP group but it did not reach 
control levels (Fig. 8). 
Caspase-3 activity 
Caspase-3 activity levels are presented in Figure 9. 
Caspase-3 activity was higher in the MPTP group 
compared to the control group. DHA treatment had 
no effect on caspase-3 activity in the DHA + MPTP 
group compared to the MPTP group. 
Discussion
In the present study, we evaluated the effects of 
DHA treatment on mice subjected to the experimen-
tal model of Parkinson’s disease. The PD model was 
developed by MPTP injection, and we have found 
that DHA treatment has a restorative effect on 
locomotion. Additionally, the role of nNOS and its 
phosphorylation in the DHA’s restorative effect on 
locomotor activity was investigated and the results 
were supported by biochemical and immunohisto-
chemical findings. In the MPTP mouse model of 
PD, as a neurotoxin MPTP crosses the blood brain 
barrier (BBB). It is metabolized into 1-methyl 4-phe-
nylpridinium (MPP+) and selectively affects the mes-
encephalic dopaminergic neurons [29]. The MPTP 
dose defines the level of damage to dopaminergic 
neurons. While the MPTP technique fails when ad-
ministered to rats, it is known that C57BL/6 mice are 
more susceptible to systemic MPTP administration 
than other murine strains. Thus, we used this model 
in our study and administered four doses consistent 
Figure 5. Neuronal nitric oxide synthase (nNOS)-immunoreactivity of dopaminergic neurons of substantia nigra in brains 
of mice in an experimental model of Parkinson disease. The experiment was planned and groups of animals designed as 
described in the legend to Figure 1. DHA treatment did not cause any difference in the expression of nNOS of dopaminergic 
neurons compared with the control group. Immunohistochemical localizations of nNOS were prominent in the cytoplasm 
of neurons with an increased expression in the MPTP and DHA + MPTP groups compared to the control group (arrows). 
However, DHA treatment decreased the nNOS expression in the DHA + MPTP group compared to the MPTP group 
(arrows). Magnifications, 40×; scale bars 50 μm; n = 5 in each group.
Control
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with the literature (4 × 20 mg/kg) every two hours 
intraperitoneally [17].
It was shown that DHA, which is important for 
brain function, changes the composition of fatty acids 
in the brain’s neuronal membranes when it is given as 
a supplement [30]. DHA is used at various concentra-
tions (10–100 mg/kg/day) in neurobiological studies 
[31, 32]. We used the dose we found to be effective 
but not toxic as shown in our previous studies [33, 
34].To identify successful implementation of PD in 
Figure 6. Phosphorylated neuronal nitric oxide synthase (p-nNOS)-immunoreactivity of dopaminergic neurons of substantia 
nigra in brains of mice in an experimental model of Parkinson disease. The experiment was planned and groups of animals 
designed as described in the legend to Figure 1. DHA treatment did not cause any difference in the expression of p-nNOS 
of neurons compared to the control group. Immunohistochemical localizations of p-nNOS were prominent in the cytoplasm 
of neurons with an increased expression in the MPTP and DHA + MPTP groups compared to the control group (arrows). 
However, DHA treatment caused p-nNOS expression to increase in the DHA + MPTP group compared to the MPTP group 
(arrows). Magnifications, 40×; scale bars 50 μm; n = 5 in each group.
Figure 7. The effect of DHA on nitrate/nitrite levels that rep-
resent oxidized forms of NO in the supernatants of substantia 
nigra (SN) in an experimental model of Parkinson’s disease. 
The experiment was planned and groups of animals designed 
as described in the legend to Figure 1. Data are means ± SEM, 
n = 6 in each group. *p < 0.05 vs. control group. 
#p < 0.05 vs. MPTP group. 
Figure 8. The effect of DHA on 4-hydroxynonenal (4-HNE) 
levels that represent lipid peroxidation in the supernatants of 
substantia nigra (SN) in an experimental model of Parkinson’s 
disease. The experiment was planned and groups of animals 
designed as described in the legend to Figure 1. Data are 
means ± SEM, n = 6 in each group. *p < 0.05 vs. control 
group. #p < 0.05 vs. MPTP group. 
Control
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animals behavioral tests, such as bradykinesia levels, 
locomotor activity and motor coordination must be 
performed. One of the commonly used tests for this 
purpose is the measurement of bradykinesia by a pole 
test. In the present study, it was observed in the MPTP 
group that the initiation of movement was delayed 
and the time to go down was prolonged. We found 
that pretreatment with DHA before the injection 
of MPTP neurotoxin restored bradykinesia in the 
DHA + MPTP group. This is an important finding 
that underscores the restorative potential of DHA 
supplementation in this experimental model of PD. 
In this study, the locomotor activity test parameters 
(ambulatory activity, total distance and total loco-
motor activities) were decreased by MPTP injection. 
DHA administration significantly improved the per-
formances of the MPTP intoxicated mice although 
it did not reach control levels. In a previous study, 
it has been shown that the administration of DHA 
(100 mg/kg) reduced dyskinesia and restored motor 
activity disorders in MPTP-intoxicated monkeys [31].
Rotarod test mainly involves the motor perfor-
mance and balance of mice. In recent study, DHA ad-
ministration improved these parameters in MPTP-in-
toxicated mice as it was seen in the other motor tests. 
In a previous study it was shown that the diet consisting 
of regular chow supplemented with 0.8% ethyl-eicosap-
entaenoate (E-EPA) prolongs the time on the rotarod 
in MPTP-injected (10 × 25 mg/kg) rats [35].
TH is the rate-limiting enzyme in the synthesis of 
catecholamines [36]. TH-immunoreactive cells are 
densely located in the SN and extend to the striatum. 
The loss of TH (+) neurons in the SN causes an es-
timated 70–80% depletion of dopamine (DA) in the 
striatum [37]. Therefore, TH is generally a phenotypic 
marker for identifying and counting dopaminergic 
neurons and has been often used as an indicator 
of dopaminergic neuron damage [38]. In an earlier 
study, it was shown that n-3 PUFA enriched diet ex-
hibits neuroprotective effect against MPTP-induced 
neurotoxicity [19]. In the present study, when the 
histological slices were examined, it was seen that 
the number of neurons in SN decreased by 75% in 
the MPTP group and the neurons decreased by 50% 
in the DHA + MPTP group. Altogether, our data 
show that the experimental PD model was developed 
successfully and that DHA had a protective effect.
Nitric oxide is one of the many agents that causes 
the formation of free radicals and is a very reactive 
and unstable gas. It is a neurotransmitter in the basal 
ganglia of the central nervous system (CNS), and it is 
known that its synthesis increases in PD [39]. Previ-
ous studies have shown that the activity of iNOS and 
nNOS, which plays a role in the synthesis of NO, also 
has a role in the developing of neurodegeneration in 
PD [40]. Also the results of our study revealed that 
the amount of nitrate/nitrite (breakdown products of 
NO) commonly used as indicators of NO tissue levels, 
increased in the SN of MPTP group, most probably 
as a result of nNOS and iNOS induction by MPTP. In 
previous studies, it was found that the nitrate/nitrite 
levels increased in the MPTP or 6-OHDA-induced rat 
models of PD [41, 42]. In our study, the administration 
of DHA to the MPTP-treated mice decreased the 
nitrate/nitrite levels in substantia nigra. This might 
be related to the phosphorylation of nNOS or sup-
pression of NO synthesis because of lower L-arginin 
entry into the cell. In previous studies it was proposed 
that omega-3 acids decrease the catalytic activity of 
nNOS through calcium-calmodulin-dependent pro-
tein kinases, which facilitate the phosphorylation of 
nNOS at serine 847 [43, 44]. Therefore, in our study, 
the suppressive effect of DHA on nitrate/nitrite levels 
may be associated with the serine 852 phosphorylation 
of nNOS which was shown to decrease since nNOS 
activity decreases when the protein is phosphorylated 
at the inhibition site of Ser847 [14]. For this reason, 
we used the serine 852 antibody that corresponded to 
Ser847 in the mouse to identify the effect of DHA on 
nNOS phosphorylation. Although nNOS phosphoryl-
ation was slightly expressed in the control and DHA 
groups, it was found that nNOS phosphorylation at 
serine 852 was increased in the DHA+MPTP group 
compared to the MPTP group. To our knowledge, 
there are no studies suggesting that the protective 
effect of DHA treatment in experimental PD may 
be mediated by nNOS phosphorylation, so this is an 
original and new finding.
Figure 9. The effect of DHA on Caspase-3 activity levels that 
represent apoptosis in the supernatants of substantia nigra 
(SN) in an experimental model of Parkinson’s disease. The 
experiment was planned and groups of animals designed as 
described in the legend to Figure 1. Data are means ± SEM, 
n = 6 in each group. *p < 0.05 vs. control group.
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The balance between free radical production and 
its neutralization by a complex antioxidant system is 
disturbed in SN of PD patients [45]. The high content 
of unsaturated fatty acids in the CNS makes this tis-
sue susceptible to free radicals’ attack. Free radicals 
cause oxidation of lipids in the cell membranes and 
lead to important changes in cell functions by forming 
lipid peroxidation products [46]. Because the free 
radicals have short half-lives and low concentrations 
and are highly reactive, they are difficult to measure 
[47]. In our study, the 4-HNE method has been used 
to identify the lipid peroxidation caused by oxidative 
damage. Oxidative stress leads to the degradation 
of very unstable lipid hydroperoxides by elimination 
reactions and the formation of secondary products 
such as aldehydes like cytotoxic 4-HNE [48]. Oxy-
gen radicals are secondary toxic messengers of lipid 
peroxidation. It is known that lipid peroxidation and 
the 4-HNE level in SN increases in PD [49]. This in-
crease intensifies the activation of caspases 3–8 what 
leads to apoptosis [50] and formation of a-synuclein 
aggregates [51]. In this study we found that the in-
jection of MPTP increased nigral 4-HNE amount. 
These findings are consistent with the literature data 
[52, 53]. In our study, the administration of DHA 
decreased the content of 4-HNE in the substantia 
nigra of DHA+MPTP group. In a previous study, 
it was found that the gene expression of antioxidant 
enzymes are upregulated by omega-3 fatty acids and 
they downregulate the genes related with the produc-
tion of reactive oxygen species (ROS) [54]. 
MPTP inhibits the respiratory chain in the mito-
chondria and increases superoxide generation [29]. 
It also activates NOS and causes nitrative stress [55]. 
The increase in free radicals leads to the release of 
mitochondrial cytochrome-c [56]. Seven copies of 
a heterodimer between apoptotic protease-activat-
ing factor 1 (Apaf-1) and cytochrome c (cytc) form 
apoptosome which leads to activation of initiator 
caspase-9 that activates caspase-3 [57]. The indicator 
of apoptosis is caspase-3 enzyme activity. Besides the 
increase of free radicals, lipid peroxidation is also 
effective in the initiation of apoptosis [58]. In our 
study, caspase-3 activity in the substantia nigra was 
increased after MPTP treatment. When DHA was 
administered, nigral caspase-3 activity was slightly 
suppressed, however, this decrease was not significant 
compared to the MPTP group. 
However, it has to be stressed that DHA does not 
produce its effects only on above mentioned path-
ways: it is known that DHA affects the characteristics 
instead of the cellular membrane [59], retinoid 
X receptors [60], and the dopamine transporter (DAT) 
activity of the cellular membrane [61]. It was shown 
that PUFA produces its effects by decreasing the 
transformation of MPTP to MPP+ and monoamine 
oxidase-B (MAO-B) activity [62].
Finally, in our study, it was identified that DHA has 
restorative effects on MPTP-induced motor activity 
disturbances, lipid peroxidation and apoptosis in the 
experimental mice model of PD. The serine 852 phos-
phorylation of nNOS may have a role in this protective 
effect. However, further studies are warranted to fully 
elucidate the protective mechanisms of DHA.
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